中东和非洲抗体药物偶联物市场预测至 2030 年 - 区域分析 - 按技术（可裂解接头和不可裂解接头）、应用（血液癌、乳腺癌、卵巢癌、尿路上皮癌等）和分销渠道（医院）药房、零售药房和在线药房）
不断发展的战略合作伙伴关系开发抗体药物偶联物推动中东和非洲抗体药物偶联物市场
抗体药物偶联物（ADC）在癌症治疗方面受到了全世界的广泛关注。 2020年，多家制药公司建立了合作伙伴关系来开发ADC。例如，2020年7月，阿斯利康和第一三共合作开发并商业化DS-1062。 DS-1602 是第一三共专有的滋养层细胞表面抗原 2 (TROP2) 导向的 ADC，用于治疗多种肿瘤类型。
同样，2022 年 12 月，默克公司 (MSD) 与四川科伦药业股份有限公司子公司科伦生物合作开发了七种用于治疗癌症的研究性临床前 ADC。根据协议，默沙东获得科伦生物科技公司的全球独家许可，以研究、开发、制造和商业化多种临床前 ADC 疗法。此外，默沙东还拥有为 ADC 候选人获得额外许可的独家选项。
同样，2023年4月，BioNTech SE与Duuality Biologics（苏州）有限公司签署战略合作协议，开发下一代ADC来治疗癌症和自身免疫性疾病。根据合作协议，BioNTech SE 将获得 DualityBios 的主要候选药物 DB-1303。 DB-1303 是一种基于拓扑异构酶 1 抑制剂的 ADC，针对人表皮生长因子受体 2 (HER2)。 HER2 是大多数癌症类型中过度表达的共同靶标，有助于癌细胞的侵袭性生长和扩散。其次，BioNTech SE 将获得另一种基于拓扑异构酶 1 抑制剂的 ADC 候选药物 DB-1311。公司的目标是在全球范围内改造和商业化创新疗法。
中东和非洲抗体药物偶联物市场概述
中东和非洲抗体药物偶联物市场分为阿联酋、南非、沙特阿拉伯以及中东和非洲其他地区。政府加强药物开发的举措和癌症病例的增加正在推动该地区的市场。沙特阿拉伯政府对药物开发做出了显着贡献，预计这将推动未来抗体药物偶联物市场的发展。例如，2023年6月18日，沙特阿拉伯全球投资组织公共投资基金（PIF）推出了商业规模合同开发和制造组织（CDMO）Lifera。 CDMO 将促进当地生物/制药行业的发展，增强国家复原力，并支持沙特阿拉伯作为全球制药制造目的地的地位。 Lifera 将专注于生产重要的生物制药产品，包括胰岛素、疫苗、血浆疗法、单克隆抗体、细胞和基因疗法以及创新小分子。该公司还将与领先的本地和国际公司建立合作伙伴关系，并吸引有针对性的投资，以提高本地产能并加强该领域的国内制造。
此外，2022 年 6 月，一种名为曲妥珠单抗 deruxtecan (T-DXd) 的抗体药物组合减缓了晚期乳腺癌患者的肿瘤生长。对 557 名晚期乳腺癌患者进行的临床试验表明，抗体药物组合有助于延长患者的预期寿命。因此，上述因素将推动未来抗体药物偶联物市场的发展。
中东和非洲抗体药物偶联物市场收入和预测到 2030 年（百万美元）
中东和非洲抗体药物偶联物市场细分
中东和非洲抗体药物偶联物市场根据技术、应用、分销渠道和国家进行细分。
根据技术，中东和非洲抗体药物偶联物市场抗体药物偶联物市场分为可裂解接头和不可裂解接头。到 2022 年，可裂解接头部分将占据更大的份额。
根据应用，中东和非洲抗体药物偶联物市场抗体药物偶联物市场细分为血癌、乳腺癌、卵巢癌、尿路上皮癌和其他的。乳腺癌细分市场在 2022 年占据最大份额。
根据分销渠道，中东和非洲抗体药物偶联物市场抗体药物偶联物市场分为医院药房、零售药房和在线药房。 2022 年，医院药房领域占据最大份额。
根据国家/地区，中东和非洲抗体药物偶联物市场分为南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区。沙特阿拉伯将在 2022 年主导中东和非洲抗体药物偶联物市场。
辉瑞公司、罗氏公司、葛兰素史克公司、吉利德科学公司、阿斯利康公司和安斯泰来制药公司都是一些领先公司在中东和非洲抗体药物偶联物市场开展业务。
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Antibody Drug Conjugates Market - Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market - Middle East & Africa Market Analysis
5.1 Middle East & Africa Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
6. Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology
6.1 Overview
6.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application
7.1 Overview
7.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Antibody Drug Conjugates Market - Country Analysis
9.1 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 Middle East & Africa Antibody Drug Conjugates Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
9.1.3 Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
9.1.3.1 Saudi Arabia
9.1.3.1.1 Overview
9.1.3.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 UAE
9.1.3.2.1 Overview
9.1.3.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.3 UAE: Antibody Drug Conjugates Market, by Technology
9.1.3.2.4 UAE: Antibody Drug Conjugates Market, by Application
9.1.3.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 South Africa
9.1.3.3.1 Overview
9.1.3.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 South Africa: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.4 Rest of Middle East & Africa
9.1.3.4.1 Overview
9.1.3.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
9.1.3.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
9.1.3.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Middle East & Africa Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 14. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 15. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 16. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 17. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 18. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. Middle East & Africa Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. Middle East & Africa Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Middle East & Africa Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: Middle East & Africa Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Middle East & Africa Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
Figure 21. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa antibody drug conjugates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution